This menu provides the list of EV mRNAs identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Maximum false positive rate (FPR): Maximum true positive rate (TPR):
  - FPR is the probability that an absent mRNA accidently have higher intensity than that mRNA.
  - TPR is the percentile of mRNA among the present mRNAs.
    Please see user manual in the contact us/help menu for detail.
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Since there are multiple primers in the microarray, the same mRNA can have several FPR and TPR values.

mRNA name UniProt accession FPR TPR Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
(FPR<0.05,TPR<0.5)
Adenylate cyclase type 6 (EC 4.6.1.1) (ATP pyrophosphate-lyase 6) (Adenylate cyclase type VI) (Adenylyl cyclase 6) (Ca(2+)-inhibitable adenylyl cyclase)O43306 2.1e-13 2.9e-2Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.
J Am Soc Nephrol. 2009 May;20(5):1053-67. doi: 10.1681/ASN.2008070798. Epub 2009 Apr 23.		COG211420 / 0 / 20
Adenylate cyclase type 6 (EC 4.6.1.1) (ATP pyrophosphate-lyase 6) (Adenylate cyclase type VI) (Adenylyl cyclase 6) (Ca(2+)-inhibitable adenylyl cyclase)O43306 3.0e-2 2.3e-1miR-1289 and Zipcode-like Sequence Enrich mRNAs in Microvesicles.
Mol Ther Nucleic Acids. 2012 Feb 7;1:e10. doi: 10.1038/mtna.2011.2.		COG211420 / 0 / 20
Adenylate cyclase type 6 (EC 4.6.1.1) (ATP pyrophosphate-lyase 6) (Adenylate cyclase type VI) (Adenylyl cyclase 6) (Ca(2+)-inhibitable adenylyl cyclase)O43306 0.0e+0 3.9e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		COG211420 / 0 / 20
Adenylate cyclase type 6 (EC 4.6.1.1) (ATP pyrophosphate-lyase 6) (Adenylate cyclase type VI) (Adenylyl cyclase 6) (Ca(2+)-inhibitable adenylyl cyclase)O43306 0.0e+0 4.3e-1First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications.
Biol Cell. 2013 Jul;105(7):289-303. doi: 10.1111/boc.201200086. Epub 2013 May 4.		COG211420 / 0 / 20
Adenylate cyclase type 6 (EC 4.6.1.1) (ATP pyrophosphate-lyase 6) (Adenylate cyclase type VI) (Adenylyl cyclase 6) (Ca(2+)-inhibitable adenylyl cyclase)O43306 0.0e+0 3.2e-1The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma.
J Cancer. 2016 Sep 27;7(14):1960-1967. eCollection 2016.		COG211420 / 0 / 20
Adenylate cyclase type 6 (EC 4.6.1.1) (ATP pyrophosphate-lyase 6) (Adenylate cyclase type VI) (Adenylyl cyclase 6) (Ca(2+)-inhibitable adenylyl cyclase)O43306 0.0e+0 3.2e-1The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma.
J Cancer. 2016 Sep 27;7(14):1960-1967. eCollection 2016.		COG211420 / 0 / 20
[1]